Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 16:50
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
Microsoft Closed Its Activision Deal. These Stocks Stand to Gain.
Andrew Tate advocates for 'angry aggressive' men possessing 'warlord qualities', Internet calls him 'epitome of a douche bag'
What to expect from Apple's big MacBook Air announcement at WWDC 2023
Telegram to launch its own version of Stories
The best travel app is an iPhone feature you're probably ignoring
Parents protest California school board after social studies curriculum rejected
Thoughtful teenager leaves inspiring 'ding dong ditch' doorbell cam message
Does xQc gamble? When and how did pro Twitch streamer lose nearly $1M?